This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi, S. T.
Right arrow Articles by Duggal, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi, S. T.
Right arrow Articles by Duggal, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2008, p. 675-683, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.00834-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase{triangledown}

Stephanie T. Shi,* Koleen J. Herlihy, Joanne P. Graham, Shella A. Fuhrman, Chau Doan, Hans Parge, Michael Hickey, Jingjin Gao, Xiu Yu, Fannie Chau, Javier Gonzalez, Hui Li, Cristina Lewis, Amy K. Patick, and Rohit Duggal

Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Drive, San Diego, California 92121

Received 26 June 2007/ Returned for modification 3 August 2007/ Accepted 4 October 2007

A novel class of nonnucleoside hepatitis C virus (HCV) polymerase inhibitors characterized by a dihydropyrone core was identified by high-throughput screening. Crystallographic studies of these compounds in complex with the polymerase identified an allosteric binding site close to the junction of the thumb and finger domains, approximately 30 Å away from the catalytic center. AG-021541, a representative compound from this series, displayed measurable in vitro antiviral activity against the HCV genotype 1b subgenomic replicon with a mean 50% effective concentration of 2.9 µM. To identify mutations conferring in vitro resistance to AG-021541, resistance selection was carried out using HCV replicon cells either by serial passages in increasing concentrations of AG-021541 or by direct colony formation at fixed concentrations of the compound. We identified several amino acid substitutions in the AG-021541-binding region of the polymerase, including M423(T/V/I), M426T, I482(S/T), and V494A, with M423T as the predominant change observed. These mutants conferred various levels of resistance to AG-021541 and structurally related compounds but remained sensitive to interferon and HCV polymerase inhibitors known to interact with the active site or other allosteric sites of the protein. In addition, dihydropyrone polymerase inhibitors retained activity against replicons that contain signature resistance changes to other polymerase inhibitors, including S282T, C316N, M414T, and P495(S/L), indicating their potential to be used in combination therapies with these polymerase inhibitors. AG-021541-resistant replicon cell lines provide a valuable tool for mechanism-of-action studies of dihydropyrone polymerase inhibitors. The clinical relevance of in vitro resistance to HCV polymerase inhibitors remains to be investigated.

* Corresponding author. Mailing address: Department of Virology, Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Drive, San Diego, CA 92121. Phone: (858) 526-4906. Fax: (858) 526-4349. E-mail: stephanie.shi{at}pfizer.com

{triangledown} Published ahead of print on 10 December 2007.

Antimicrobial Agents and Chemotherapy, February 2008, p. 675-683, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.00834-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shi, S. T., Herlihy, K. J., Graham, J. P., Nonomiya, J., Rahavendran, S. V., Skor, H., Irvine, R., Binford, S., Tatlock, J., Li, H., Gonzalez, J., Linton, A., Patick, A. K., Lewis, C. (2009). Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother. 53: 2544-2552 [Abstract] [Full Text]  
  • Herlihy, K. J., Graham, J. P., Kumpf, R., Patick, A. K., Duggal, R., Shi, S. T. (2008). Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors. Antimicrob. Agents Chemother. 52: 3523-3531 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»